Literature DB >> 22982802

Primary hyperparathyroidism.

John P Bilezikian1.   

Abstract

OBJECTIVE: To review primary hyperparathyroidism and the key issues that are relevant to the practicing endocrinologist.
METHODS: The latest information on the presentation, diagnosis, and traditional and nontraditional aspects of primary hyperparathyroidism is reviewed.
RESULTS: The diagnosis of primary hyperparathyroidism is straightforward when the traditional hypercalcemic patient is documented to have an elevated parathyroid hormone (PTH) level. Commonly, patients are identified who have normal serum calcium levels but elevated PTH levels in whom no secondary causes for hyperparathyroidism can be confirmed. Traditional target organs of primary hyperparathyroidism-the skeleton and the kidneys-continue to be a focus in the patient evaluation. Bone mineral density shows a typical pattern of involvement with the distal one-third radius being selectively reduced compared with the lumbar spine in which bone mineral density is generally well maintained. Neurocognitive and cardiovascular aspects of primary hyperparathyroidism, while a focus of recent interest, have not been shown to definitively aid in the decision for or against surgery. The recommendation for surgery in primary hyperparathyroidism is based on guidelines that focus on the serum calcium level, renal function, bone mineral density, and age. In patients who do not meet guidelines, a nonsurgical management approach has merit.
CONCLUSIONS: Primary hyperparathyroidism is continuing to show changes in its clinical profile, with normocalcemic primary hyperparathyroidism being a topic of great interest. Skeletal and renal features of primary hyperparathyroidism drive, in most cases, the decision to recommend surgery. In patients who do not meet any criteria for surgery, a conservative approach with appropriate monitoring is acceptable.

Entities:  

Mesh:

Year:  2012        PMID: 22982802     DOI: 10.4158/EP12166.RA

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  7 in total

1.  Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai.

Authors:  Jian-Min Liu; Natalie E Cusano; Barbara C Silva; Lin Zhao; Xiao-Yan He; Bei Tao; Li-Hao Sun; Hong-Yan Zhao; Wen-Wei Fan; Megan E Romano; Guang Ning; John P Bilezikian
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

2.  Insulin sensitivity in normocalcaemic primary hyperparathyroidism.

Authors:  F Tassone; M Maccario; L Gianotti; C Baffoni; M Pellegrino; S Cassibba; F Cesario; G Magro; G Borretta
Journal:  Endocrine       Date:  2013-09-25       Impact factor: 3.633

Review 3.  [Metabolic disorders as paraneoplastic syndromes].

Authors:  S Krug; P Michl
Journal:  Internist (Berl)       Date:  2018-02       Impact factor: 0.743

4.  Phosphate homeostasis in Bartter syndrome: a case-control study.

Authors:  Alberto Bettinelli; Cristina Viganò; Maria Cristina Provero; Francesco Barretta; Alessandra Albisetti; Silvana Tedeschi; Barbara Scicchitano; Mario G Bianchetti
Journal:  Pediatr Nephrol       Date:  2014-06-06       Impact factor: 3.714

5.  Muscle function is impaired in patients with "asymptomatic" primary hyperparathyroidism.

Authors:  Lars Rolighed; Anne Kristine Amstrup; Niels Frederik Breum Jakobsen; Tanja Sikjaer; Leif Mosekilde; Peer Christiansen; Lars Rejnmark
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

Review 6.  Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Authors:  Aibek E Mirrakhimov
Journal:  N Am J Med Sci       Date:  2015-11

7.  Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.

Authors:  Martin B Niederle; Ursula Foeger-Samwald; Philipp Riss; Andreas Selberherr; Christian Scheuba; Peter Pietschmann; Bruno Niederle; Katharina Kerschan-Schindl
Journal:  Langenbecks Arch Surg       Date:  2019-08-26       Impact factor: 3.445

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.